Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.

Xuexin HeJiali JiMei TianFrancisco J EstevaGabriel N HortobagyiSai-Ching Jim Yeung

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Adjuvant chemotherapy plus trastuzumab should be recommended for patients with pT1N0M0 HER2+ BC ≥0.8 cm in diameter; adjuvant therapy may not be necessary for tumors <0.8 cm.

Keyphrases

positive breast cancer
epidermal growth factor receptor
metastatic breast cancer
lymph node
tyrosine kinase
optic nerve